BERRY GENOMICS CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.23 CNY | +2.90% |
|
+6.09% | -19.88% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 11,312 | 12,979 | 13,348 | 6,804 | 4,034 | 4,073 |
| Enterprise Value (EV) 1 | 10,888 | 12,766 | 13,074 | 6,781 | 4,044 | 4,024 |
| P/E ratio | 42 x | 33.3 x | 63.4 x | -62.6 x | -13.9 x | -9.52 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 7.86 x | 8.02 x | 8.67 x | 4.78 x | 2.95 x | 3.54 x |
| EV / Revenue | 7.56 x | 7.89 x | 8.49 x | 4.77 x | 2.96 x | 3.49 x |
| EV / EBITDA | 26.9 x | 25 x | 44.4 x | 135 x | -96.8 x | -40.7 x |
| EV / FCF | -104 x | -73.5 x | 113 x | -32.4 x | 272 x | 19.4 x |
| FCF Yield | -0.96% | -1.36% | 0.89% | -3.09% | 0.37% | 5.14% |
| Price to Book | 5.94 x | 5.57 x | 5.59 x | 2.75 x | 1.75 x | 2.18 x |
| Nbr of stocks (in thousands) | 354,606 | 354,606 | 350,698 | 350,698 | 353,521 | 353,521 |
| Reference price 2 | 31.90 | 36.60 | 38.06 | 19.40 | 11.41 | 11.52 |
| Announcement Date | 4/23/19 | 4/14/20 | 4/28/21 | 4/14/22 | 4/7/23 | 4/24/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,440 | 1,618 | 1,540 | 1,422 | 1,368 | 1,151 |
| EBITDA 1 | 405 | 511.2 | 294.7 | 50.17 | -41.78 | -98.87 |
| EBIT 1 | 338.4 | 429.1 | 218.6 | -46.41 | -132.4 | -198.8 |
| Operating Margin | 23.51% | 26.53% | 14.19% | -3.26% | -9.68% | -17.27% |
| Earnings before Tax (EBT) 1 | 310.9 | 445.7 | 245.3 | -120.4 | -283.3 | -453.4 |
| Net income 1 | 268.1 | 390.6 | 210.7 | -110.8 | -254.8 | -427.2 |
| Net margin | 18.62% | 24.15% | 13.68% | -7.79% | -18.62% | -37.1% |
| EPS 2 | 0.7600 | 1.100 | 0.6000 | -0.3100 | -0.8200 | -1.210 |
| Free Cash Flow 1 | -104.3 | -173.8 | 116 | -209.4 | 14.89 | 207 |
| FCF margin | -7.25% | -10.74% | 7.53% | -14.73% | 1.09% | 17.97% |
| FCF Conversion (EBITDA) | - | - | 39.35% | - | - | - |
| FCF Conversion (Net income) | - | - | 55.06% | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/23/19 | 4/14/20 | 4/28/21 | 4/14/22 | 4/7/23 | 4/24/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | -11.93 |
| Net margin | - |
| EPS 2 | -0.0400 |
| Dividend per Share | - |
| Announcement Date | 4/14/22 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 10.1 | - |
| Net Cash position 1 | 424 | 212 | 274 | 22.7 | - | 48.4 |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.2419 x | - |
| Free Cash Flow 1 | -104 | -174 | 116 | -209 | 14.9 | 207 |
| ROE (net income / shareholders' equity) | 14.8% | 18.1% | 8.63% | -4.44% | -10.4% | -20.1% |
| ROA (Net income/ Total Assets) | 10.6% | 10.2% | 4.33% | -0.86% | -2.46% | -4.18% |
| Assets 1 | 2,525 | 3,821 | 4,867 | 12,920 | 10,343 | 10,218 |
| Book Value Per Share 2 | 5.370 | 6.570 | 6.810 | 7.040 | 6.510 | 5.270 |
| Cash Flow per Share 2 | 1.190 | 1.160 | 1.790 | 1.180 | 0.9400 | 0.9600 |
| Capex 1 | 166 | 295 | 113 | 337 | 73.3 | 55.1 |
| Capex / Sales | 11.52% | 18.25% | 7.31% | 23.67% | 5.36% | 4.79% |
| Announcement Date | 4/23/19 | 4/14/20 | 4/28/21 | 4/14/22 | 4/7/23 | 4/24/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.88% | 452M | |
| -17.21% | 8.46B | |
| +50.91% | 3.88B | |
| -34.71% | 2.63B | |
| -8.41% | 2.45B | |
| -9.64% | 2.31B | |
| -3.77% | 1.99B | |
| -17.29% | 1.61B | |
| -36.54% | 1.3B | |
| +5.98% | 1.09B |
- Stock Market
- Equities
- 000710 Stock
- Financials Berry Genomics Co.,Ltd